Gilead enlists Cancer Genetics to perform leukemia trials

Gilead Sciences appointed Cancer Genetics to head up international clinical trials in an effort to diagnose patients with chronic lymphocytic leukemia. Using its SelectOne program, Cancer Genetics will use diagnostic assays and microarrays in a series of tests for cancer-specific biomarkers associated with leukemia. Chronic lymphocytic leukemia is the most common from of the disease in the western hemisphere and affects over 110,000 people in the U.S., according to Cancer Genetics. More

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.